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Abstract: We report a patient with psoriatic arthritis (PsA) who was successfully treated with adalimumab even while under hemodialysis 
therapy for associated chronic renal failure. Flow cytometry of circulating lymphocytes revealed an obvious decrease in both Th1 and 
Th17 cells after starting adalimumab. The latter returned to the pretreatment level in the course of adalimumab therapy, while the former 
did not. Adalimumab is a potent therapeutic option for PsA patients with chronic renal failure on hemodialysis, and Th1 in peripheral 
blood may reflect the disease activity.
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Introduction
Psoriasis  is  a  chronic  inflammatory  skin  disease 
characterized  clinically  by  red  scaly  patches 
developing in any part of the body with a relapse-
remitting  course.  Systemic  arthritis  complicates 
psoriasis  in  approximately  20%  of  the  patients,1 
and its clinical picture resembles that of rheumatoid 
arthritis  with  regard  to  therapeutic  efficacy  of  the 
monoclonal  anti-tumor  necrosis  factor  (TNF)-α 
antibody, such as infliximab and adalimumab. Several 
recent reports have demonstrated that T-helper 1 cells 
(Th1), T-helper 17 cells (Th17) and regulatory T cells 
(Treg) may play a central role in the pathogenesis of 
psoriatic arthritis (PsA) via interaction with dendritic 
cells,  leading  to  accelerated  production  of  TNF.2,3 
Here, we report a patient with PsA associated with 
chronic  renal  failure  on  hemodialysis  who  was 
successfully  treated  with  adalimumab  alone.  Flow 
cytometry showed a persistent decrease in Th1 cells 
after starting adalimumab, and we postulate that this 
circulating lymphocyte subpopulation may be useful 
as a therapeutic marker of PsA.
case Report
A  57-year-old  man  with  a  9-year  history  of 
hemodialysis  for  chronic  renal  failure  due  to 
glomerulonephritis  became  aware  of  arthralgia  in 
multiple joints with no precipitating cause. He was 
treated with oral prednisolone at a dose of 5 to 7.5 mg 
daily in a neighboring hospital, but systemic arthralgia 
worsened  gradually.  When  he  was  referred  to  our 
hospital, physical examination showed swelling and 
tenderness in bilateral proximal interphalangeal (PIP) 
joints, wrists, knees, ankles and metatarsophalangeal 
joints with no significant skin lesions. Laboratory tests 
demonstrated an increase in inflammatory reactions, 
such  as  C-reactive  protein  (CRP)  (1.28  mg/dL, 
normal ,0.1 mg/dL) and renal dysfunction (creatinine 
4.28 mg/dL, normal 0.6–1.0 mg/dL; blood urea nitrogen 
78.5 mg/dL, normal 8–20 mg/dL) but no positive results 
in  autoantibodies,  including  rheumatoid  factor  and 
the anti-cyclic citrullinated peptide and anti-nuclear 
antibodies.  The  X-ray  showed  mild  bone  erosions 
on PIP joints. The disease activity score including a 
28-joint count (DAS28)-CRP calculated according to 
the approved formula (http://www.  das-score.nl/) was 
3.79. Salazosulfapyridine at 1000 mg daily could not 
sufficiently relieve his arthralgia.
Approximately 10 months later he noticed eruptions 
on his head, elbows, fingers and knees with hyper-
keratosis and discoloration in his nails, which were 
clinically diagnosed as psoriasis by a dermatologist, 
in conjunction with worsening of his systemic arthri-
tis and elevations of CRP (3.31 mg/dL) (Fig. 1). The 
psoriasis area and severity index (PASI) was relatively 
low  (6.0),  but  DAS28-CRP  indicated  high  disease 
activity of arthritis (6.88). Adalimumab was started 
at 80 mg initially, followed by 40 mg every other 
week. The patient showed dramatic improvement of 
his arthritis as well as psoriasis, and DAS28-CRP and 
PASI decreased to 2.41 and 2.8, respectively, 2 weeks 
after starting adalimumab (Fig. 2). On flow cytometry 
before treatment CD4+ interferon-γ+ (Th1) and CD4+ 
interleukin-17+ (Th17) cells in peripheral blood were 
higher than those of age-matched healthy controls, 
but  CD4+CD25+FOXP-3+  cells  (Treg)  showed  no 
obvious increase. All of these lymphocyte subpopu-
lations  were  decreased  eight  weeks  after  starting 
adalimumab  compared  with  before  (Fig.  2).  CD4+ 
interleukin-4+ cells (T-helper 2) showed no signifi-
cant change before and after treatment. Twelve weeks 
after starting adalimumab, CD4+ interleukin-17+ and 
CD4+CD25+FOXP-3+ cells returned to the pretreat-
ment level but CD4+ interferon-γ+ cells remained at 
low levels. He has since been in good general health 
A B
C
Figure  1.  The  patient  showed  psoriatic  eruptions  on  the  surface  of 
hemodialysis shunt (A) and on the left knee (B) with hyperkeratosis and 
­ discoloration­in­fingernails­(c).Adalimumab in psA on hemodialysis
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with no arthralgia or adverse events under regular 
administration of adalimumab.
Discussion
The  present  patient  was  diagnosed  as  having  PsA 
based on polyarthritis with skin and nail lesions char-
acteristic of psoriasis. In approximately 19% of PsA 
polyarthritis has been reported to precede psoriasis, 
as  seen  in  the  present  patient.4  Methotrexate  and 
cyclosporine A are usually potent therapeutic options 
for PsA, but these drugs were inadequate in the pres-
ent patient because of chronic renal failure requiring 
hemodialysis.5 Biologics are the next choice. Several 
recent reports have demonstrated that early use of bio-
logics can ameliorate polyarthralgia and skin lesions 
in rheumatic disorders, including PsA, associated with 
chronic renal failure on hemodialysis (Table 1).5–12 
Biologics targeting TNF are most frequently used in 
this situation, and among them etanercept has been 
reported to show pharmacokinetics similar to those 
in healthy subjects even under chronic renal failure 
on hemodialysis.13 However, the use of etanercept is 
not allowed in PsA in Japan. In the present patient, 
therefore, we decided to employ adalimumab, which 
is a human anti-TNF-α monoclonal antibody usable 
in  PsA  without  coadministrations  of  methotrexate. 
The usual dose of adalimumab is 40 mg, but 80 mg 
was selected as an initial dose in the present patient 
because of severe systemic arthritis.14 Soon after start-
ing this drug both polyathritis and psoriasis improved 
in parallel with a decrease in inflammatory reactions. 
The patient has so far shown no serious adverse events 
ascribable to adalimumab.
In the present patient we serially analyzed pheno-
types  of  peripheral  blood  lymphocytes  using  flow 
cytometry. Th1 and Th17 cells showed significantly 
higher levels before treatment compared with those 
of age-matched healthy controls as described in the 
previous report from another institute,2 but Treg cells 
did not. These 3 lymphocyte subpopulations manifestly 
decreased  8  weeks  after  starting    adalimumab. 
Th17  and  Treg  cells  returned  to  the  pretreatment 
level  12  weeks  after  starting  adalimumab,  while 
Th1 cells remained at low levels in conjunction with 
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Figure 2. The­clinical­profile­of­the­patient.
note: *Mean ± 2SD in 10 age-matched healthy subjects.
Abbreviations: CRp, C-reactive protein; DAS28, disease activity score including a 28-joint count; IFN, interferon; IL, interleukin; pASI, psoriasis area and 
severity index; SASp, salazosulfapyridine.Shimojima et al
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the suppressed activity of PsA. The decreases in Th1, 
Th17 and Treg cells after treatment are ascribable to 
3 possible mechanisms. The first is a direct cytotoxic 
effect of adalimumab. This drug can react with TNF-α 
in peripheral blood but also with that expressed on 
immune competent cells, including T lymphocytes.15 
The interaction between TNF-α on the cell surface 
and  adalimumab  may  have  produced  cytotoxicity, 
resulting  in  a  rapid  elimination  of Th1, Th17  and 
Treg cells. The second possible mechanism is anti-
TNF-mediated  induction  or  recovery  of  cell  populations 
capable of regulating Th1 and Th17 cells.16 Treg cells 
are  suitable  candidates,  but  in  the  present  patient 
this  subpopulation  was  simultaneously  decreased 
8 weeks after starting adalimumab. The third possible 
mechanism is inhibition of circulating TNF-α, which 
has multipotentials on immune systems. As TNF-α can 
promote differentiation and maturation of T cells,2,16 
adalimumab-induced  reduction  of  this  cytokine  in 
peripheral  blood  may  have  caused  alterations  of 
T-lymphocyte subpopulations as seen in the present 
patient.  The  reincreases  in  Th17  and  Treg  cells 
12 weeks after starting treatment are probably due to 
rapid differentiation or mobilization into peripheral 
blood via some other stimulating mediators, such as 
interleukin-2  and  transforming  growth  factor-β17–19 
although the precise mechanisms are unclear. Chronic 
renal  failure  itself  also  has  a  positive  effect  on 
Th17 cells irrespective of maintenance hemodialysis.20 
Considering that Th1 cells were the only lymphocytes 
showing  obvious  change  persistently  after  starting 
adalimumab in the present patient, this subpopulation 
may be able to more sensitively reflect disease activity 
of PsA than Th17 and Treg.
In conclusion, adalimumab monotherapy is a potent 
therapeutic option in patients with PsA with regard to 
clinical efficacy and safety even under hemodialysis 
for associated chronic renal failure. Further studies 
in a set of patients are necessary in order to clarify 
whether or not Th1 cells are a useful clinical marker 
indicating disease activity of PsA.
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